36 results on '"Portincasa, P"'
Search Results
2. Immediate Breast Reconstruction in Skin-Reducing Mastectomy with Prepectoral Polyuretane (Pu) Implant Covered with an Autologous Dermo-Adipose Flap
- Author
-
Lembo, Fedele, Cecchino, Liberato Roberto, Parisi, Domenico, and Portincasa, Aurelio
- Published
- 2024
- Full Text
- View/download PDF
3. Bridging current knowledge gap: better primary colorectal cancer prevention in people living with metabolic dysfunction-associated steatotic liver
- Author
-
Di Ciaula, Agostino and Portincasa, Piero
- Published
- 2024
- Full Text
- View/download PDF
4. Contrasting obesity: is something missing here?
- Author
-
Di Ciaula, Agostino and Portincasa, Piero
- Published
- 2024
- Full Text
- View/download PDF
5. Reducing the hospitalization epidemic of chronic heart failure by disease management programs
- Author
-
Belfiore, Anna, Stranieri, Rosa, Novielli, Maria Elena, and Portincasa, Piero
- Published
- 2024
- Full Text
- View/download PDF
6. Surgical approach to a rare case of Beckwith Wiedemann syndrome with left thigh hyperplasia
- Author
-
F. Gesuete, M. Molle, L. Cagiano, L. Annacontini, V. Verdura, G.F. Nicoletti, G. Ferraro, D. Parisi, and A. Portincasa
- Subjects
Beckwith-wiedemann syndrome ,Vertical thigh lift ,Hemihyperplasia ,Psycological well being ,Surgery of rare case ,Body simmetrization ,Surgery ,RD1-811 - Abstract
Thigh lift surgery is generally performed in patients with severe weight loss outcomes, particularly those undergoing bariatric surgery. However, there are other congenital malformation conditions that may require the same treatment, such as Beckwith Wideman syndrome.
- Published
- 2024
- Full Text
- View/download PDF
7. Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA Network registries
- Author
-
Antonio Vitale, Valeria Caggiano, Abdurrahman Tufan, Gaafar Ragab, Ezgi Deniz Batu, Piero Portincasa, Emma Aragona, Jurgen Sota, Giovanni Conti, Amato De Paulis, Donato Rigante, Alma Nunzia Olivieri, Ali Şahin, Francesco La Torre, Giuseppe Lopalco, Marco Cattalini, Maria Cristina Maggio, Antonella Insalaco, Petros P. Sfikakis, Elena Verrecchia, Derya Yildirim, Hamit Kucuk, Riza Can Kardas, Ahmed Hatem Laymouna, Mahmoud Ghanema, Moustafa Ali Saad, Seher Sener, Hulya Ercan Emreol, Seza Ozen, Nour Jaber, Mohamad Khalil, Agostino Di Ciaula, Carla Gaggiano, Giuseppe Malizia, Andrea Affronti, Serena Patroniti, Meri Romeo, Jessica Sbalchiero, Francesca Della Casa, Ilaria Mormile, Sara Silvaroli, Maria Francesca Gicchino, Neşe Çabuk Çelik, Maria Tarsia, Anastasios Karamanakos, José Hernández-Rodríguez, Paola Parronchi, Daniela Opris-Belinski, Patrizia Barone, Andreas Recke, Stefania Costi, Paolo Sfriso, Henrique A. Mayrink Giardini, Stefano Gentileschi, Ewa Wiesik-Szewczyk, Ibrahim Vasi, Roberta Loconte, Karina Jahnz-Różyk, Eduardo Martín-Nares, Jiram Torres-Ruiz, Alberto Cauli, Alessandro Conforti, Giacomo Emmi, Francesca Li Gobbi, Giovanni Rosario Biasi, Riccardo Terribili, Piero Ruscitti, Emanuela Del Giudice, Samar Tharwat, Antonio Luca Brucato, Benson Ogunjimi, Andrea Hinojosa-Azaola, Alberto Balistreri, Claudia Fabiani, Bruno Frediani, and Luca Cantarini
- Subjects
autoinflammatory diseases ,FMF ,tumor ,neoplasm ,rare diseases ,treatment ,Immunologic diseases. Allergy ,RC581-607 - Abstract
ObjectiveInflammation has been associated with an increased risk for cancer development, while innate immune system activation could counteract the risk for malignancies. Familial Mediterranean fever (FMF) is a severe systemic inflammatory condition and also represents the archetype of innate immunity deregulation. Therefore, the aim of this study is to investigate the risk for cancer development in FMF.MethodsThe risk ratio (RR) for malignancies was separately compared between FMF patients and fibromyalgia subjects, Still’s disease patients and Behçet’s disease patients. Clinical variables associated with cancer development in FMF patients were searched through binary logistic regression.Results580 FMF patients and 102 fibromyalgia subjects, 1012 Behçet’s disease patients and 497 Still’s disease patients were enrolled. The RR for the occurrence of malignant neoplasms was 0.26 (95% Confidence Interval [CI.] 0.10-0.73, p=0.006) in patients with FMF compared to fibromyalgia subjects; the RR for the occurrence of malignant cancer was 0.51 (95% CI. 0.23-1.16, p=0.10) in FMF compared to Still’s disease and 0.60 (95% CI. 0.29-1.28, p=0.18) in FMF compared to Behçet’s disease. At logistic regression, the risk of occurrence of malignant neoplasms in FMF patients was associated with the age at disease onset (β1 = 0.039, 95% CI. 0.001-0.071, p=0.02), the age at the diagnosis (β1 = 0.048, 95% CI. 0.039-0.085, p=0.006), the age at the enrolment (β1 = 0.05, 95% CI. 0.007-0.068, p=0.01), the number of attacks per year (β1 = 0.011, 95% CI. 0.001- 0.019, p=0.008), the use of biotechnological agents (β1 = 1.77, 95% CI. 0.43-3.19, p=0.009), the use of anti-IL-1 agents (β1 = 2.089, 95% CI. 0.7-3.5, p=0.002).ConclusionsThe risk for cancer is reduced in Caucasic FMF patients; however, when malignant neoplasms occur, this is more frequent in FMF cases suffering from a severe disease phenotype and presenting a colchicine-resistant disease.
- Published
- 2024
- Full Text
- View/download PDF
8. A balloon is better than diet: the role of lifestyle changes in the management of obesity and steatotic liver, and need for a winning strategy
- Author
-
Di Ciaula, Agostino and Portincasa, Piero
- Published
- 2024
- Full Text
- View/download PDF
9. Converging Pathways between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Diabetes in Children
- Author
-
Maria Felicia Faienza, Ilaria Farella, Mohamad Khalil, and Piero Portincasa
- Subjects
liver ,steatosis ,obesity ,non-alcoholic fatty liver disease ,metabolic-associated (dysfunction) steatotic liver disease ,magnetic resonance imaging ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
In the past thirty years, childhood obesity rates have risen significantly worldwide, affecting over 340 million children in affluent nations. This surge is intricately tied to metabolic disorders, notably insulin resistance, type 2 diabetes mellitus (T2DM), and the continually evolving spectrum of metabolic-associated (dysfunction) steatotic liver disease (MASLD). This review underscores the alarming escalation of childhood obesity and delves comprehensively into the evolving and dynamic changes of nomenclature surrounding diverse conditions of hepatic steatosis, from the initial recognition of non-alcoholic fatty liver disease (NAFLD) to the progressive evolution into MASLD. Moreover, it emphasizes the crucial role of pediatric endocrinologists in thoroughly and accurately investigating MASLD onset in children with T2DM, where each condition influences and exacerbates the progression of the other. This review critically highlights the inadequacies of current screening strategies and diagnosis, stressing the need for a paradigm shift. A proposed solution involves the integration of hepatic magnetic resonance imaging assessment into the diagnostic arsenal for children showing insufficient glycemic control and weight loss post-T2DM diagnosis, thereby complementing conventional liver enzyme testing. This holistic approach aims to significantly enhance diagnostic precision, fostering improved outcomes in this vulnerable high-risk pediatric population.
- Published
- 2024
- Full Text
- View/download PDF
10. Borderline Case in Reconstructive Plastic Surgery of the Lower Limb Treated with Bone Drilling and Use of Dermal Regeneration Template
- Author
-
Vincenzo Verdura, MD, Luigi Cagiano, MD, Marcello Molle, MD, Pasquale Bisceglia, MD, Nicola Fini, MD, Luigi Annacontini, MD, Vincenzo Mazzarella, MD, Domenico Parisi, MD, and Aurelio Portincasa, MD
- Subjects
Surgery ,RD1-811 - Abstract
Summary:. The traumatic pathology of the lower limb represents a very complex branch of medicine, which, despite the wide presence of guidelines, aimed at regulating the various therapeutic procedures, and is still greatly influenced by random variables and by the multiple responses to treatments. In this report, we present our experience with a borderline case, where the timing of the trauma and the patient’s characteristics made it difficult to use the most recommended procedures in trauma management.
- Published
- 2024
- Full Text
- View/download PDF
11. Supplementation with Thymbra spicata extract ameliorates lifespan, body-weight gain and Paraquat-induced oxidative stress in Drosophila melanogaster: An age- and sex-related study
- Author
-
Farah Diab, Daniela Beghelli, Anna Nuccitelli, Giulio Lupidi, Mohamad Khalil, Piero Portincasa, and Laura Vergani
- Subjects
Thymbra spicata extract ,Dietary polyphenols ,Drosophila melanogaster ,Aging ,Body weight ,Antioxidant defense ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Aging represents a decline in function over time. Polyphenols are dietary antioxidants that could exert beneficial effects on aging. This study investigated the effects of dietary supplementation with two extracts from Thymbra spicata L. aerial parts on the lifespan, body-weight control, and antioxidant responses of Drosophila melanogaster cohorts distinguished for age and sex. The aqueous extract extended the lifespan of young female flies, and this pro-longevity potential was associated with a reduction in the body-weight gain. Furthermore, the aqueous extract promoted the antioxidant defense when young females were exposed to Paraquat by reducing oxidative stress and mortality. This study provides the first insight into the beneficial effects of T. spicata supplementation in an animal model, suggesting that the healthy effect could mainly depend on strengthening the antioxidant defenses which reflect on the lifespan. Further investigations will better clarify the mechanisms and potential of T. spicata as nutraceutics in anti-aging strategies.
- Published
- 2024
- Full Text
- View/download PDF
12. Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective
- Author
-
Gyorgy Baffy and Piero Portincasa
- Subjects
intrahepatic vascular resistance ,portal hypertension ,endohepatology ,EUS-guided measurement of portal pressure gradient ,Microbiology ,QR1-502 - Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common condition with heterogeneous outcomes difficult to predict at the individual level. Feared complications of advanced MASLD are linked to clinically significant portal hypertension and are initiated by functional and mechanical changes in the unique sinusoidal capillary network of the liver. Early sinusoidal vasoregulatory changes in MASLD lead to increased intrahepatic vascular resistance and represent the beginning of portal hypertension. In addition, the composition and function of gut microbiota in MASLD are distinctly different from the healthy state, and multiple lines of evidence demonstrate the association of dysbiosis with these vasoregulatory changes. The gut microbiota is involved in the biotransformation of nutrients, production of de novo metabolites, release of microbial structural components, and impairment of the intestinal barrier with impact on innate immune responses, metabolism, inflammation, fibrosis, and vasoregulation in the liver and beyond. The gut–liver axis is a conceptual framework in which portal circulation is the primary connection between gut microbiota and the liver. Accordingly, biochemical and hemodynamic attributes of portal circulation may hold the key to better understanding and predicting disease progression in MASLD. However, many specific details remain hidden due to limited access to the portal circulation, indicating a major unmet need for the development of innovative diagnostic tools to analyze portal metabolites and explore their effect on health and disease. We also need to safely and reliably monitor portal hemodynamics with the goal of providing preventive and curative interventions in all stages of MASLD. Here, we review recent advances that link portal metabolomics to altered sinusoidal vasoregulation and may allow for new insights into the development of portal hypertension in MASLD.
- Published
- 2024
- Full Text
- View/download PDF
13. Multidimensional Assessment of Sarcopenia and Sarcopenic Obesity in Geriatric Patients: Creatinine/Cystatin C Ratio Performs Better than Sarcopenia Index
- Author
-
Mohamad Khalil, Agostino Di Ciaula, Nour Jaber, Roberta Grandolfo, Flavia Fiermonte, and Piero Portincasa
- Subjects
sarcopenia ,bioelectrical impendence ,creatinine/cystatin C ratio ,sarcopenic index ,sarcopenic obesity ,Microbiology ,QR1-502 - Abstract
The serum creatinine/cystatin C ratio (CCR) and the sarcopenia index (SI) are novel indicators for sarcopenia, but their accuracy may depend on various confounders. To assess CCR and SI diagnostic accuracy, we studied the clinical and biophysical parameters associated with sarcopenia or sarcopenic obesity. A total of 79 elderly patients (65–99 yrs, 33 females) underwent clinical, anthropometric, body composition, geriatric performance, and blood chemistry evaluation. The CCR and SI accuracy were assessed to identify sarcopenia. Sarcopenia was confirmed in 40.5%, and sarcopenic obesity in 8.9% of the subjects. Sarcopenic patients showed an increased Charlson comorbidity index, cardiovascular disease (CVD) rates and frailty, and decreased physical performance than non-sarcopenic subjects. Patients with sarcopenic obesity had increased body fat and inflammatory markers compared to obese subjects without sarcopenia. Sarcopenia was associated with a decreased CCR and SI. However, when the logistic regression models were adjusted for possible confounders (i.e., age, gender, Charlson comorbidity index, presence of CVD, and frailty score), a significant OR was confirmed for the CCR (OR 0.021, 95% CI 0.00055–0.83) but not for the SI. The AUC for the CCR for sarcopenia discrimination was 0.72. A higher performance was observed in patients without chronic kidney diseases (CKD, AUC 0.83). CCR, more than the SI, is a useful, non-invasive, and cost-effective tool to predict sarcopenia, irrespective of the potential confounders, particularly in subjects without CKD.
- Published
- 2024
- Full Text
- View/download PDF
14. Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
- Author
-
Piero Portincasa, Mohamad Khalil, Laura Mahdi, Valeria Perniola, Valeria Idone, Annarita Graziani, Gyorgy Baffy, and Agostino Di Ciaula
- Subjects
clinical trials ,drug therapy ,fatty liver ,liver fibrosis ,MAFLD ,MASLD ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression of liver damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk of cardio-metabolic diseases and cancer. In recent years, the terminological evolution from “nonalcoholic fatty liver disease” (NAFLD) to “metabolic dysfunction-associated fatty liver disease” (MAFLD) and, finally, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been paralleled by increased knowledge of mechanisms linking local (i.e., hepatic) and systemic pathogenic pathways. As a consequence, the need for an appropriate classification of individual phenotypes has been oriented to the investigation of innovative therapeutic tools. Besides the well-known role for lifestyle change, a number of pharmacological approaches have been explored, ranging from antidiabetic drugs to agonists acting on the gut–liver axis and at a systemic level (mainly farnesoid X receptor (FXR) agonists, PPAR agonists, thyroid hormone receptor agonists), anti-fibrotic and anti-inflammatory agents. The intrinsically complex pathophysiological history of MASLD makes the selection of a single effective treatment a major challenge, so far. In this evolving scenario, the cooperation between different stakeholders (including subjects at risk, health professionals, and pharmaceutical industries) could significantly improve the management of disease and the implementation of primary and secondary prevention measures. The high healthcare burden associated with MASLD makes the search for new, effective, and safe drugs a major pressing need, together with an accurate characterization of individual phenotypes. Recent and promising advances indicate that we may soon enter the era of precise and personalized therapy for MASLD/MASH.
- Published
- 2024
- Full Text
- View/download PDF
15. Supplementation of Micro- and Macronutrients—A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- Author
-
Magdalena Tyczyńska, Gabriela Hunek, Martyna Szczasny, Adam Brachet, Jacek Januszewski, Alicja Forma, Piero Portincasa, Jolanta Flieger, and Jacek Baj
- Subjects
non-alcoholic fatty liver disease ,micronutrients ,macronutrients ,nutrition ,vitamins ,unsaturated fats ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Non-alcoholic fatty liver disease (NAFLD) is a condition in which the pathological cumulation of fat with coexisting inflammation and damage of hepatic cells leads to progressive dysfunctions of the liver. Except for the commonly well-known major causes of NAFLD such as obesity, dyslipidemia, insulin resistance, or diabetes, an unbalanced diet and imbalanced nutritional status should also be taken into consideration. In this narrative review, we summarized the current knowledge regarding the micro- and macronutrient status of patients suffering from NAFLD considering various diets and supplementation of chosen supplements. We aimed to summarize the knowledge indicating which nutritional impairments may be associated with the onset and progression of NAFLD at the same time evaluating the potential therapy targets that could facilitate the healing process. Except for the above-mentioned objectives, one of the most important aspects of this review was to highlight the possible strategies for taking care of NAFLD patients taking into account the challenges and opportunities associated with the micronutrient status of the patients. The current research indicates that a supplementation of chosen vitamins (e.g., vitamin A, B complex, C, or D) as well as chosen elements such as zinc may alleviate the symptoms of NAFLD. However, there is still a lack of sufficient data regarding healthy ranges of dosages; thus, further research is of high importance in this matter.
- Published
- 2024
- Full Text
- View/download PDF
16. Nutritional and Physiological Properties of Thymbra spicata: In Vitro Study Using Fecal Fermentation and Intestinal Integrity Models
- Author
-
Mohamad Khalil, Francesca Piccapane, Mirco Vacca, Giuseppe Celano, Laura Mahdi, Valeria Perniola, Carmen Aurora Apa, Alessandro Annunziato, Ilaria Iacobellis, Giuseppe Procino, Maria Calasso, Maria De Angelis, Rosa Caroppo, and Piero Portincasa
- Subjects
Thymbra spicata ,carvacrol ,gut microbiota ,intestinal permeability ,polyphenols ,Nutrition. Foods and food supply ,TX341-641 - Abstract
(Poly)phenolic-rich Mediterranean plants such as Thymbra spicata have been associated with several health-promoting effects. The nutritional value, as well as physiological interaction of T. spicata with the gastrointestinal tract, has not been investigated before. The nutritional composition of T. spicata leaves was here characterized by standard analytical methods. T. spicata leaves were subjected to ethanolic extraction, simulated gastrointestinal digestion, and anaerobic microbial gut fermentation. Phenols/flavonoid contents and radical scavenging activity were assessed by colorimetric methods. The volatile organic compounds (VOCs) were detected by gas chromatography coupled with mass spectrometry. The effect on intestinal integrity was evaluated using a Caco-2 monolayers mounted in a Ussing chamber. T. spicata contains a high amount of fiber (12.3%) and unsaturated fatty acids (76% of total fat). A positive change in VOCs including short-chain fatty acids was observed without significant change in viable microbe. T. spicata and carvacrol (main phenolic compound) enhanced ionic currents in a concentration-dependent manner without compromising the Caco-2 monolayer’s integrity. These effects were partially lost upon simulated digestion and completely abolished after colonic fermentation in line with polyphenols and carvacrol content. Conclusion: T. spicata represents a promising nutrient for the modulation of gut microbiota and the gut barrier. Further studies must better define its mechanisms of action.
- Published
- 2024
- Full Text
- View/download PDF
17. T.12.5: MECHANISTIC ANALYSIS OF FACTORS ASSOCIATED WITH POST COVID-19 IBS OCCURRENCE
- Author
-
Hod, K., primary, Marasco, G., additional, Cremon, C., additional, Barbaro, M.R., additional, Colecchia, L., additional, Kagramanova, A., additional, Bordin, D., additional, Drug, V., additional, Fusaroli, P., additional, Mohamed, S.Y., additional, Ricci, C., additional, Bellini, M., additional, Rahman, M.M., additional, Melcarne, L., additional, Santos, J., additional, Bor, S., additional, Yapali, S., additional, Lukic, S., additional, Trajkovska, M., additional, Dumitrascu, D., additional, Pietrangelo, A., additional, Ghoshal, U., additional, Kolokolnikova, O., additional, Colecchia, A., additional, Serra, J., additional, Marconi, G., additional, Danese, S., additional, Portincasa, P., additional, Maggio, M., additional, Philippou, E., additional, Lee, Y.Y., additional, Stanghellini, V., additional, and Barbara, G., additional
- Published
- 2024
- Full Text
- View/download PDF
18. Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA Network registries
- Author
-
Vitale, A, Caggiano, V, Tufan, A, Ragab, G, Batu, Ed, Portincasa, P, Aragona, E, Sota, J, Conti, G, De Paulis, A, Rigante, Donato, Olivieri, An, S ̧ahin, A, La Torre, F, Lopalco, G, Cattalini, M, Maggio, Mc, Insalaco, A, Sfikakis, Pp, Verrecchia, Elena, Yildirim, D, Kucuk, H, Kardas, Rc, Laymouna, Ah, Ghanema, M, Saad, Ma, Sener, S, Ercan Emreol, H, Ozen, S, Jaber, N, Khalil, M, Di Ciaula, A, Gaggiano, C, Malizia, G, Affronti, A, Patroniti, S, Romeo, M, Sbalchiero, J, Della Casa, F, Mormile, I, Silvaroli, Sara, Gicchino, Mf, Çelik, Nç, Tarsia, M, Karamanakos, A, Hernández-Rodríguez, J, Parronchi, P, Opris-Belinski, D, Barone, P, Recke, A, Costi, S, Sfriso, P, Giardini, Ham, Gentileschi, S, Wiesik-Szewczyk, E, Vasi, I, Loconte, R, Jahnz-Różyk, K, Martín-Nares, E, Torres-Ruiz, J, Cauli, A, Conforti, A, Emmi, G, Li Gobbi, F, Biasi, Gr, Terribili, R, Ruscitti, P, Del Giudice, E, Tharwat, S, Brucato, Al, Ogunjimi, B, Hinojosa-Azaola, A, Balistreri, A, Fabiani, C, Frediani, B, Cantarini, L, Rigante D (ORCID:0000-0001-7032-7779), Verrecchia E, Silvaroli S, Vitale, A, Caggiano, V, Tufan, A, Ragab, G, Batu, Ed, Portincasa, P, Aragona, E, Sota, J, Conti, G, De Paulis, A, Rigante, Donato, Olivieri, An, S ̧ahin, A, La Torre, F, Lopalco, G, Cattalini, M, Maggio, Mc, Insalaco, A, Sfikakis, Pp, Verrecchia, Elena, Yildirim, D, Kucuk, H, Kardas, Rc, Laymouna, Ah, Ghanema, M, Saad, Ma, Sener, S, Ercan Emreol, H, Ozen, S, Jaber, N, Khalil, M, Di Ciaula, A, Gaggiano, C, Malizia, G, Affronti, A, Patroniti, S, Romeo, M, Sbalchiero, J, Della Casa, F, Mormile, I, Silvaroli, Sara, Gicchino, Mf, Çelik, Nç, Tarsia, M, Karamanakos, A, Hernández-Rodríguez, J, Parronchi, P, Opris-Belinski, D, Barone, P, Recke, A, Costi, S, Sfriso, P, Giardini, Ham, Gentileschi, S, Wiesik-Szewczyk, E, Vasi, I, Loconte, R, Jahnz-Różyk, K, Martín-Nares, E, Torres-Ruiz, J, Cauli, A, Conforti, A, Emmi, G, Li Gobbi, F, Biasi, Gr, Terribili, R, Ruscitti, P, Del Giudice, E, Tharwat, S, Brucato, Al, Ogunjimi, B, Hinojosa-Azaola, A, Balistreri, A, Fabiani, C, Frediani, B, Cantarini, L, Rigante D (ORCID:0000-0001-7032-7779), Verrecchia E, and Silvaroli S
- Abstract
Objective: Inflammation has been associated with an increased risk for cancer development, while innate immune system activation could counteract the risk for malignancies. Familial Mediterranean fever (FMF) is a severe systemic inflammatory condition and also represents the archetype of innate immunity deregulation. Therefore, the aim of this study is to investigate the risk for cancer development in FMF. Methods: The risk ratio (RR) for malignancies was separately compared between FMF patients and fibromyalgia subjects, Still’s disease patients and Behçet’s disease patients. Clinical variables associated with cancer development in FMF patients were searched through binary logistic regression. Results: 580 FMF patients and 102 fibromyalgia subjects, 1012 Behçet’s disease patients and 497 Still’s disease patients were enrolled. The RR for the occurrence of malignant neoplasms was 0.26 (95% Confidence Interval [CI.] 0.10-0.73, p=0.006) in patients with FMF compared to fibromyalgia subjects; the RR for the occurrence of malignant cancer was 0.51 (95% CI. 0.23-1.16, p=0.10) in FMF compared to Still’s disease and 0.60 (95% CI. 0.29-1.28, p=0.18) in FMF compared to Behçet’s disease. At logistic regression, the risk of occurrence of malignant neoplasms in FMF patients was associated with the age at disease onset (b1 = 0.039, 95% CI. 0.001-0.071, p=0.02), the age at the diagnosis (b1 = 0.048, 95% CI. 0.039-0.085, p=0.006), the age at the enrolment (b1 = 0.05, 95% CI. 0.007-0.068, p=0.01), the number of attacks per year (b1 = 0.011, 95% CI. 0.001- 0.019, p=0.008), the use of biotechnological agents (b1 = 1.77, 95% CI. 0.43-3.19, p=0.009), the use of anti-IL-1 agents (b1 = 2.089, 95% CI. 0.7- 3.5, p=0.002). Conclusions: The risk for cancer is reduced in Caucasic FMF patients; however, when malignant neoplasms occur, this is more frequent in FMF cases suffering from a severe disease phenotype and presenting a colchicine-resistant disease.
- Published
- 2024
19. T.12.8: EFFECTS OF RAMADAN INTERMITTENT FASTING ON GASTROINTESTINAL MOTILITY AND GASTROINTESTINAL SYMPTOMS IN HEALTHY SUBJECTS.
- Author
-
Abdallah, H., Khalil, M., Farella, I., Lanza, E., Santoro, S., Di Ciaula, A., and Portincasa, P.
- Published
- 2024
- Full Text
- View/download PDF
20. Supplementation with Thymbra spicata extract ameliorates lifespan, body-weight gain and Paraquat-induced oxidative stress in Drosophila melanogaster: An age- and sex-related study.
- Author
-
Diab, Farah, Beghelli, Daniela, Nuccitelli, Anna, Lupidi, Giulio, Khalil, Mohamad, Portincasa, Piero, and Vergani, Laura
- Abstract
[Display omitted] • Thymbra spicata extracts as dietary supplements for Drosophila melanogaster flies differentiated by age and gender. • The T. spicata aqueous extract (TW) extends the lifespan of young females. • The pro-longevity potential is associated with a reduced body-weight gain and improved antioxidant defense. • Thymbra spicata potential as nutraceutics for anti-ageing strategies. Aging represents a decline in function over time. Polyphenols are dietary antioxidants that could exert beneficial effects on aging. This study investigated the effects of dietary supplementation with two extracts from Thymbra spicata L. aerial parts on the lifespan, body-weight control, and antioxidant responses of Drosophila melanogaster cohorts distinguished for age and sex. The aqueous extract extended the lifespan of young female flies, and this pro-longevity potential was associated with a reduction in the body-weight gain. Furthermore, the aqueous extract promoted the antioxidant defense when young females were exposed to Paraquat by reducing oxidative stress and mortality. This study provides the first insight into the beneficial effects of T. spicata supplementation in an animal model, suggesting that the healthy effect could mainly depend on strengthening the antioxidant defenses which reflect on the lifespan. Further investigations will better clarify the mechanisms and potential of T. spicata as nutraceutics in anti-aging strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Ramadan Intermittent Fasting: A Potential Modulatory Approach to Gut Microbiota and Metabolic Disturbances?
- Author
-
Di Ciaula A, Khalil M, and Portincasa P
- Subjects
- Humans, Intermittent Fasting, Fasting, Gastrointestinal Microbiome physiology, Islam
- Published
- 2024
- Full Text
- View/download PDF
22. Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children.
- Author
-
Faienza MF, Farella I, Khalil M, and Portincasa P
- Subjects
- Humans, Child, Insulin Resistance, Pediatric Obesity metabolism, Pediatric Obesity complications, Fatty Liver metabolism, Fatty Liver pathology, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 complications, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease pathology
- Abstract
In the past thirty years, childhood obesity rates have risen significantly worldwide, affecting over 340 million children in affluent nations. This surge is intricately tied to metabolic disorders, notably insulin resistance, type 2 diabetes mellitus (T2DM), and the continually evolving spectrum of metabolic-associated (dysfunction) steatotic liver disease (MASLD). This review underscores the alarming escalation of childhood obesity and delves comprehensively into the evolving and dynamic changes of nomenclature surrounding diverse conditions of hepatic steatosis, from the initial recognition of non-alcoholic fatty liver disease (NAFLD) to the progressive evolution into MASLD. Moreover, it emphasizes the crucial role of pediatric endocrinologists in thoroughly and accurately investigating MASLD onset in children with T2DM, where each condition influences and exacerbates the progression of the other. This review critically highlights the inadequacies of current screening strategies and diagnosis, stressing the need for a paradigm shift. A proposed solution involves the integration of hepatic magnetic resonance imaging assessment into the diagnostic arsenal for children showing insufficient glycemic control and weight loss post-T2DM diagnosis, thereby complementing conventional liver enzyme testing. This holistic approach aims to significantly enhance diagnostic precision, fostering improved outcomes in this vulnerable high-risk pediatric population.
- Published
- 2024
- Full Text
- View/download PDF
23. Distinct biophysiological effects of Ramadan fasting and traditional intermittent fasting on markers of body fat storage. A real-life study.
- Author
-
Khalil M, Abdallah H, Jaber N, Garruti G, Di Ciaula A, and Portincasa P
- Abstract
Background: Ramadan Intermittent fasting (RIF) exerts beneficial metabolic effects and improves gastrointestinal motility. However, a comparison between RIF and the traditional 16-hours intermittent fasting (16IF), a strategy for weight loss, is lacking., Methods: A total of 34 subjects (median age 32.5 years, range 18-63 years; median BMI 24.5 Kg m
-1 ², range 18.6-37.6 Kg m-1 ²) were assigned to RIF (N = 18) or 16IF (N = 16) for 30 days. We measured variations in anthropometric measures (BMI, waist, and abdominal circumference), serum insulin, glucose, cortisol, non-esterified fatty acid (NEFA), body fat composition (bioelectrical impedance analysis), and the ultrasonographic measurements of liver steatosis (Hepatorenal index, HRI) and thickness of subcutaneous (SAT) and visceral (VAT) fats., Results: At baseline, BMI, rates of liver steatosis and distribution of normal weight, overweight, and obese subjects were comparable between the two groups. Body weight significantly decreased at the end of fasting in both RIF (-4.2 % vs baseline, P = 0.002) and 16IF (-2.1 % vs baseline, P = 0.002). Waist and abdominal circumferences significantly decreased only in RIF as well as the amount of body fat. In subjects with liver steatosis, SAT and VAT significantly decreased following RIF, but not 16h-IF, as well as the ultrasonographic HRI., Conclusion: Both 16IF and RIF are able, during 1-month, to reduce body weight. However, RIF but not 16IF also generates marked beneficial effects in terms of reduced subcutaneous fat and liver steatosis. Further studies urge to verify the effects of different models of IF in weight-cycling and long-term management of obesity and related dysmetabolic conditions, such as ectopic fat over-storage., Competing Interests: Declaration of competing interest All the authors report having no relevant conflicts of interest for this article., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
24. Advances in the pathophysiology, diagnosis and management of chronic diarrhoea from bile acid malabsorption: a systematic review.
- Author
-
Di Ciaula A, Khalil M, Baffy G, and Portincasa P
- Abstract
Bile acid malabsorption (BAM) is an important disorder of digestive pathophysiology as it generates chronic diarrhoea. This condition originates from intricate pathways involving bile acid synthesis and metabolism in the liver and gut, the composition of gut microbiota, enterohepatic circulation and key receptors as farnesoid X receptor (FXR), fibroblast growth factor receptor 4 (FGFR4), and the G-protein bile acid receptor-1 (GPBAR-1). Although symptoms can resemble those related to disorders of gut brain interaction, accurate diagnosis of BAM may greatly benefit the patient. The empiric diagnosis of BAM is primarily based on the clinical response to bile acid sequestrants. Specific tests including the 48-hour fecal bile acid test, serum levels of 7α-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19 (FGF19), and the
75 Selenium HomotauroCholic Acid Test (SeHCAT) are not widely available. Nevertheless, lack of diagnostic standardization of BAM may account for poor recognition and delayed management. Beyond bile acid sequestrants, therapeutic approaches include the use of FXR agonists, FGF19 analogues, glucagon-like peptide-1 (GLP-1) receptor agonists, and microbiota modulation. These novel agents can best make their foray into the therapeutic armamentarium if BAM does not remain a diagnosis of exclusion. Ignoring BAM as a specific condition may continue to contribute to increased healthcare costs and reduced quality of life. Here, we aim to provide a comprehensive review of the pathophysiology, diagnosis, and management of BAM., Competing Interests: Conflict-of-interest statement All the authors report having no relevant conflicts of interest for this article., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
25. Early and accurate diagnosis of steatotic liver by artificial intelligence (AI)-supported ultrasonography.
- Author
-
Santoro S, Khalil M, Abdallah H, Farella I, Noto A, Dipalo GM, Villani P, Bonfrate L, Di Ciaula A, and Portincasa P
- Subjects
- Humans, Male, Female, Middle Aged, Prospective Studies, Adult, Aged, Liver diagnostic imaging, Liver pathology, Early Diagnosis, Artificial Intelligence, Ultrasonography methods, Fatty Liver diagnostic imaging, Magnetic Resonance Imaging methods, Algorithms, ROC Curve
- Abstract
Objectives: Steatotic liver disease is the most frequent chronic liver disease worldwide. Ultrasonography (US) is commonly employed for the assessment and diagnosis. Few information is available on the possible use of artificial intelligence (AI) to ameliorate the diagnostic accuracy of ultrasonography., Materials and Methods: An AI-based algorithm was developed using a dataset of US images. We prospectively enrolled 134 patients for algorithm validation. Patients underwent abdominal US and Proton Density Fat Fraction MRI scans (MRI-PDFF), assumed as reference technique. The hepatorenal index was manually calculated (HRIM) by 4 operators. An automatic hepatorenal index (HRIA) was obtained by the algorithm. The accuracy of HRIA to discriminate steatosis grades was evaluated by ROC analysis using MRI-PDFF cut-offs., Results: Overweight was 40 % of subjects (BMI 26.4 kg/cm
2 ). The median HRIA was 1.11 (IQR 0.32) and the average of 4 manually calculated HRIM was 1.08 (IQR 0.26), with a 15 % inter-operator variability. Both HRIA (R = 0.79, P < 0.0001) and HRIM (R = 0.69, P < 0.0001) significantly correlated with liver fat percentage (MRI-PDFF). According to MRI-PDFF, 32 % of enrolled subjects had steatosis. Discrimination capacity by AUC between patient with steatosis and patient without steatosis was better for HRIA than HRIM (AUC: 0.87 vs. 0.82, respectively). ROC analysis showed an AUC = 0.98 for HRIA with 1.64 cut-off in distinguishing between mild and moderate/severe groups., Conclusions: The use of AI improves accuracy and speed of ultrasonography in the diagnosis of liver steatosis. Further studies should evaluate the routine use of this technique in the management of liver steatosis at high cardio-metabolic risk., Competing Interests: Declaration of competing interest None declared., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
26. Gender-specific insights into the irritable bowel syndrome pathophysiology. Focus on gut dysbiosis and permeability.
- Author
-
JohnBritto JS, Di Ciaula A, Noto A, Cassano V, Sciacqua A, Khalil M, Portincasa P, and Bonfrate L
- Subjects
- Humans, Sex Factors, Female, Male, Quality of Life, Gastrointestinal Motility physiology, Irritable Bowel Syndrome physiopathology, Irritable Bowel Syndrome microbiology, Dysbiosis physiopathology, Gastrointestinal Microbiome physiology, Permeability, Brain-Gut Axis physiology
- Abstract
Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder involving the brain-gut interaction. IBS is characterized by persistent abdominal pain and changes in bowel habits. IBS exerts significant impacts on quality of life and imposes huge economic costs. Global epidemiological data reveal variations in IBS prevalence, both globally and between genders, necessitating comprehensive studies to uncover potential societal and cultural influences. While the exact pathophysiology of IBS remains incompletely understood, the mechanism involves a dysregulation of the brain-gut axis, leading to disturbed intestinal motility, local inflammation, altered intestinal permeability, visceral sensitivity, and gut microbiota composition. We reviewed several gender-related pathophysiological aspects of IBS pathophysiology, by focusing on gut dysbiosis and intestinal permeability. This perspective paves the way to personalized and multidimensional clinical management of individuals with IBS., Competing Interests: Declaration of competing interest The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper., (Copyright © 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective.
- Author
-
Baffy G and Portincasa P
- Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common condition with heterogeneous outcomes difficult to predict at the individual level. Feared complications of advanced MASLD are linked to clinically significant portal hypertension and are initiated by functional and mechanical changes in the unique sinusoidal capillary network of the liver. Early sinusoidal vasoregulatory changes in MASLD lead to increased intrahepatic vascular resistance and represent the beginning of portal hypertension. In addition, the composition and function of gut microbiota in MASLD are distinctly different from the healthy state, and multiple lines of evidence demonstrate the association of dysbiosis with these vasoregulatory changes. The gut microbiota is involved in the biotransformation of nutrients, production of de novo metabolites, release of microbial structural components, and impairment of the intestinal barrier with impact on innate immune responses, metabolism, inflammation, fibrosis, and vasoregulation in the liver and beyond. The gut-liver axis is a conceptual framework in which portal circulation is the primary connection between gut microbiota and the liver. Accordingly, biochemical and hemodynamic attributes of portal circulation may hold the key to better understanding and predicting disease progression in MASLD. However, many specific details remain hidden due to limited access to the portal circulation, indicating a major unmet need for the development of innovative diagnostic tools to analyze portal metabolites and explore their effect on health and disease. We also need to safely and reliably monitor portal hemodynamics with the goal of providing preventive and curative interventions in all stages of MASLD. Here, we review recent advances that link portal metabolomics to altered sinusoidal vasoregulation and may allow for new insights into the development of portal hypertension in MASLD., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
28. Early diagnosis and management of cardiac amyloidosis: A clinical perspective.
- Author
-
Bellofatto IA, Schindler TH, Portincasa P, Carbone F, Canepa M, Liberale L, and Montecucco F
- Subjects
- Humans, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial therapy, Early Diagnosis, Amyloidosis diagnosis, Amyloidosis therapy, Cardiomyopathies therapy, Cardiomyopathies diagnosis, Patient Care Team
- Abstract
Cardiac amyloidosis multidisciplinary team (MDT). We propose the creation of a multidisciplinary team (MDT) for cardiac amyloidosis in which internal medicine physicians could take a lead role in coordinating other specialists involved in patient care. Created with BioRender.com., (© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
29. Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology.
- Author
-
Portincasa P and Baffy G
- Subjects
- Humans, Metabolic Syndrome, Metabolic Diseases, Terminology as Topic, Non-alcoholic Fatty Liver Disease
- Abstract
The medical term nonalcoholic fatty liver disease (NAFLD) was coined in 1986 for a condition that has since become the most prevalent liver disorder worldwide. In the last 3 years, the global professional community launched 2 consecutive efforts to purge NAFLD from the medical dictionary and recommended new terms based on disease pathophysiology rather than distinction from similar conditions featuring liver steatosis. A consensus by renowned clinical scholars primarily residing in the Asian-Pacific region introduced metabolic dysfunction-associated fatty liver disease (MAFLD) as a new name to replace NAFLD in 2020. In 2023, a nomenclature and classification resulting in the term metabolic dysfunction-associated steatotic liver disease (MASLD) was developed by a large expert panel under the auspices of leading liver societies from Europe and Americas. These marked and rapid shifts in nomenclature have garnered the attention of many researchers and clinicians across the globe due to the multilevel impact of a frequent and potentially progressive chronic liver disease in both adult and pediatric populations. The proposed terminologies differ in several ways but they have more in common than differences. They both capture key features of liver disease associated with cardiometabolic risk factors and with significant impact on all-cause and liver-related mortality. The framework of MASLD has incorporated many innovative aspects of MAFLD and while several conceptual disparities remain a work in progress, global efforts should focus on new insights into disease pathogenesis, outcome trajectories, prevention, and treatment. Here, some of these challenges are discussed to facilitate this process., Competing Interests: Declaration of competing interest All the authors report having no relevant conflicts of interest for this article, (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
30. Multidimensional Assessment of Sarcopenia and Sarcopenic Obesity in Geriatric Patients: Creatinine/Cystatin C Ratio Performs Better than Sarcopenia Index.
- Author
-
Khalil M, Di Ciaula A, Jaber N, Grandolfo R, Fiermonte F, and Portincasa P
- Abstract
The serum creatinine/cystatin C ratio (CCR) and the sarcopenia index (SI) are novel indicators for sarcopenia, but their accuracy may depend on various confounders. To assess CCR and SI diagnostic accuracy, we studied the clinical and biophysical parameters associated with sarcopenia or sarcopenic obesity. A total of 79 elderly patients (65-99 yrs, 33 females) underwent clinical, anthropometric, body composition, geriatric performance, and blood chemistry evaluation. The CCR and SI accuracy were assessed to identify sarcopenia. Sarcopenia was confirmed in 40.5%, and sarcopenic obesity in 8.9% of the subjects. Sarcopenic patients showed an increased Charlson comorbidity index, cardiovascular disease (CVD) rates and frailty, and decreased physical performance than non-sarcopenic subjects. Patients with sarcopenic obesity had increased body fat and inflammatory markers compared to obese subjects without sarcopenia. Sarcopenia was associated with a decreased CCR and SI. However, when the logistic regression models were adjusted for possible confounders (i.e., age, gender, Charlson comorbidity index, presence of CVD, and frailty score), a significant OR was confirmed for the CCR (OR 0.021, 95% CI 0.00055-0.83) but not for the SI. The AUC for the CCR for sarcopenia discrimination was 0.72. A higher performance was observed in patients without chronic kidney diseases (CKD, AUC 0.83). CCR, more than the SI, is a useful, non-invasive, and cost-effective tool to predict sarcopenia, irrespective of the potential confounders, particularly in subjects without CKD.
- Published
- 2024
- Full Text
- View/download PDF
31. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
- Author
-
Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, Baffy G, and Di Ciaula A
- Subjects
- Humans, Metabolic Diseases metabolism, Metabolic Diseases etiology, Fatty Liver metabolism, Fatty Liver etiology, Fatty Liver therapy, Fatty Liver complications, Animals, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease therapy, Non-alcoholic Fatty Liver Disease drug therapy, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease etiology
- Abstract
The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression of liver damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk of cardio-metabolic diseases and cancer. In recent years, the terminological evolution from "nonalcoholic fatty liver disease" (NAFLD) to "metabolic dysfunction-associated fatty liver disease" (MAFLD) and, finally, "metabolic dysfunction-associated steatotic liver disease" (MASLD) has been paralleled by increased knowledge of mechanisms linking local (i.e., hepatic) and systemic pathogenic pathways. As a consequence, the need for an appropriate classification of individual phenotypes has been oriented to the investigation of innovative therapeutic tools. Besides the well-known role for lifestyle change, a number of pharmacological approaches have been explored, ranging from antidiabetic drugs to agonists acting on the gut-liver axis and at a systemic level (mainly farnesoid X receptor (FXR) agonists, PPAR agonists, thyroid hormone receptor agonists), anti-fibrotic and anti-inflammatory agents. The intrinsically complex pathophysiological history of MASLD makes the selection of a single effective treatment a major challenge, so far. In this evolving scenario, the cooperation between different stakeholders (including subjects at risk, health professionals, and pharmaceutical industries) could significantly improve the management of disease and the implementation of primary and secondary prevention measures. The high healthcare burden associated with MASLD makes the search for new, effective, and safe drugs a major pressing need, together with an accurate characterization of individual phenotypes. Recent and promising advances indicate that we may soon enter the era of precise and personalized therapy for MASLD/MASH.
- Published
- 2024
- Full Text
- View/download PDF
32. Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA Network registries.
- Author
-
Vitale A, Caggiano V, Tufan A, Ragab G, Batu ED, Portincasa P, Aragona E, Sota J, Conti G, De Paulis A, Rigante D, Olivieri AN, Şahin A, La Torre F, Lopalco G, Cattalini M, Maggio MC, Insalaco A, Sfikakis PP, Verrecchia E, Yildirim D, Kucuk H, Kardas RC, Laymouna AH, Ghanema M, Saad MA, Sener S, Ercan Emreol H, Ozen S, Jaber N, Khalil M, Di Ciaula A, Gaggiano C, Malizia G, Affronti A, Patroniti S, Romeo M, Sbalchiero J, Della Casa F, Mormile I, Silvaroli S, Gicchino MF, Çelik NÇ, Tarsia M, Karamanakos A, Hernández-Rodríguez J, Parronchi P, Opris-Belinski D, Barone P, Recke A, Costi S, Sfriso P, Giardini HAM, Gentileschi S, Wiesik-Szewczyk E, Vasi I, Loconte R, Jahnz-Różyk K, Martín-Nares E, Torres-Ruiz J, Cauli A, Conforti A, Emmi G, Li Gobbi F, Biasi GR, Terribili R, Ruscitti P, Del Giudice E, Tharwat S, Brucato AL, Ogunjimi B, Hinojosa-Azaola A, Balistreri A, Fabiani C, Frediani B, and Cantarini L
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Risk Factors, Cohort Studies, Young Adult, Fibromyalgia epidemiology, Fibromyalgia etiology, Behcet Syndrome epidemiology, Behcet Syndrome complications, Familial Mediterranean Fever complications, Familial Mediterranean Fever epidemiology, Neoplasms epidemiology, Neoplasms etiology, Registries
- Abstract
Objective: Inflammation has been associated with an increased risk for cancer development, while innate immune system activation could counteract the risk for malignancies. Familial Mediterranean fever (FMF) is a severe systemic inflammatory condition and also represents the archetype of innate immunity deregulation. Therefore, the aim of this study is to investigate the risk for cancer development in FMF., Methods: The risk ratio (RR) for malignancies was separately compared between FMF patients and fibromyalgia subjects, Still's disease patients and Behçet's disease patients. Clinical variables associated with cancer development in FMF patients were searched through binary logistic regression., Results: 580 FMF patients and 102 fibromyalgia subjects, 1012 Behçet's disease patients and 497 Still's disease patients were enrolled. The RR for the occurrence of malignant neoplasms was 0.26 (95% Confidence Interval [CI.] 0.10-0.73, p=0.006) in patients with FMF compared to fibromyalgia subjects; the RR for the occurrence of malignant cancer was 0.51 (95% CI. 0.23-1.16, p =0.10) in FMF compared to Still's disease and 0.60 (95% CI. 0.29-1.28, p =0.18) in FMF compared to Behçet's disease. At logistic regression, the risk of occurrence of malignant neoplasms in FMF patients was associated with the age at disease onset (β1 = 0.039, 95% CI. 0.001-0.071, p =0.02), the age at the diagnosis (β1 = 0.048, 95% CI. 0.039-0.085, p =0.006), the age at the enrolment (β1 = 0.05, 95% CI. 0.007-0.068, p =0.01), the number of attacks per year (β1 = 0.011, 95% CI. 0.001- 0.019, p =0.008), the use of biotechnological agents (β1 = 1.77, 95% CI. 0.43-3.19, p =0.009), the use of anti-IL-1 agents (β1 = 2.089, 95% CI. 0.7-3.5, p =0.002)., Conclusions: The risk for cancer is reduced in Caucasic FMF patients; however, when malignant neoplasms occur, this is more frequent in FMF cases suffering from a severe disease phenotype and presenting a colchicine-resistant disease., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Vitale, Caggiano, Tufan, Ragab, Batu, Portincasa, Aragona, Sota, Conti, De Paulis, Rigante, Olivieri, Şahin, La Torre, Lopalco, Cattalini, Maggio, Insalaco, Sfikakis, Verrecchia, Yildirim, Kucuk, Kardas, Laymouna, Ghanema, Saad, Sener, Ercan Emreol, Ozen, Jaber, Khalil, Di Ciaula, Gaggiano, Malizia, Affronti, Patroniti, Romeo, Sbalchiero, Della Casa, Mormile, Silvaroli, Gicchino, Çelik, Tarsia, Karamanakos, Hernández-Rodríguez, Parronchi, Opris-Belinski, Barone, Recke, Costi, Sfriso, Giardini, Gentileschi, Wiesik-Szewczyk, Vasi, Loconte, Jahnz-Różyk, Martín-Nares, Torres-Ruiz, Cauli, Conforti, Emmi, Li Gobbi, Biasi, Terribili, Ruscitti, Del Giudice, Tharwat, Brucato, Ogunjimi, Hinojosa-Azaola, Balistreri, Fabiani, Frediani and Cantarini.)
- Published
- 2024
- Full Text
- View/download PDF
33. Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease.
- Author
-
Tyczyńska M, Hunek G, Szczasny M, Brachet A, Januszewski J, Forma A, Portincasa P, Flieger J, and Baj J
- Subjects
- Humans, Nutritional Status, Vitamins metabolism, Vitamins administration & dosage, Dietary Supplements, Micronutrients metabolism, Non-alcoholic Fatty Liver Disease chemically induced, Non-alcoholic Fatty Liver Disease diet therapy, Non-alcoholic Fatty Liver Disease metabolism, Nutrients metabolism
- Abstract
Non-alcoholic fatty liver disease (NAFLD) is a condition in which the pathological cumulation of fat with coexisting inflammation and damage of hepatic cells leads to progressive dysfunctions of the liver. Except for the commonly well-known major causes of NAFLD such as obesity, dyslipidemia, insulin resistance, or diabetes, an unbalanced diet and imbalanced nutritional status should also be taken into consideration. In this narrative review, we summarized the current knowledge regarding the micro- and macronutrient status of patients suffering from NAFLD considering various diets and supplementation of chosen supplements. We aimed to summarize the knowledge indicating which nutritional impairments may be associated with the onset and progression of NAFLD at the same time evaluating the potential therapy targets that could facilitate the healing process. Except for the above-mentioned objectives, one of the most important aspects of this review was to highlight the possible strategies for taking care of NAFLD patients taking into account the challenges and opportunities associated with the micronutrient status of the patients. The current research indicates that a supplementation of chosen vitamins (e.g., vitamin A, B complex, C, or D) as well as chosen elements such as zinc may alleviate the symptoms of NAFLD. However, there is still a lack of sufficient data regarding healthy ranges of dosages; thus, further research is of high importance in this matter.
- Published
- 2024
- Full Text
- View/download PDF
34. Neutrophil degranulation, endothelial and metabolic dysfunction in unvaccinated long COVID patients.
- Author
-
Di Ciaula A, Liberale L, Portincasa P, Khalil M, Galerati I, Farella I, Noto A, JohnBritto S, Moriero M, Michelauz C, Frè F, Olivero C, Bertolotto M, Montecucco F, Carbone F, and Bonfrate L
- Subjects
- Humans, Follow-Up Studies, Neutrophils, Prospective Studies, SARS-CoV-2, Biomarkers, Post-Acute COVID-19 Syndrome, COVID-19
- Abstract
Background: Long COVID symptoms are widely diffused and have a poorly understood pathophysiology, with possible involvement of inflammatory cytokines., Materials and Methods: A prospective follow-up study involved 385 unvaccinated patients, started 1 month after SARS-CoV-2 infection and continued for up to 12 months. We compared circulating biomarkers of neutrophil degranulation, endothelial and metabolic dysfunction in subjects with long COVID symptoms and in asymptomatic post-COVID controls., Results: The highest occurrence of symptoms (71%) was after 3 months from the infection, decreasing to 62.3% and 29.4% at 6 and 12 months, respectively. Compared to controls, long COVID patients had increased levels of the neutrophilic degranulation indices MMP-8 and MPO, of endothelial dysfunction indices L-selectin and P-selectin. Among indices of metabolic dysfunction, leptin levels were higher in long COVID patients than in controls., Conclusion: In unvaccinated patients, symptoms may persist up to 1 year after acute COVID infection, with increased indices of neutrophil degranulation, endothelial and metabolic dysfunction. The clinical implications of specific inflammatory biomarkers require further attention, especially in individuals with fatigue and long COVID-linked cognitive dysfunctions., (© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
35. Nutritional and Physiological Properties of Thymbra spicata : In Vitro Study Using Fecal Fermentation and Intestinal Integrity Models.
- Author
-
Khalil M, Piccapane F, Vacca M, Celano G, Mahdi L, Perniola V, Apa CA, Annunziato A, Iacobellis I, Procino G, Calasso M, De Angelis M, Caroppo R, and Portincasa P
- Subjects
- Humans, Fermentation, Caco-2 Cells, Gas Chromatography-Mass Spectrometry, Phenols, Digestion, Fatty Acids, Volatile, Lamiaceae chemistry, Cymenes
- Abstract
(Poly)phenolic-rich Mediterranean plants such as Thymbra spicata have been associated with several health-promoting effects. The nutritional value, as well as physiological interaction of T. spicata with the gastrointestinal tract, has not been investigated before. The nutritional composition of T. spicata leaves was here characterized by standard analytical methods. T. spicata leaves were subjected to ethanolic extraction, simulated gastrointestinal digestion, and anaerobic microbial gut fermentation. Phenols/flavonoid contents and radical scavenging activity were assessed by colorimetric methods. The volatile organic compounds (VOCs) were detected by gas chromatography coupled with mass spectrometry. The effect on intestinal integrity was evaluated using a Caco-2 monolayers mounted in a Ussing chamber. T. spicata contains a high amount of fiber (12.3%) and unsaturated fatty acids (76% of total fat). A positive change in VOCs including short-chain fatty acids was observed without significant change in viable microbe. T. spicata and carvacrol (main phenolic compound) enhanced ionic currents in a concentration-dependent manner without compromising the Caco-2 monolayer's integrity. These effects were partially lost upon simulated digestion and completely abolished after colonic fermentation in line with polyphenols and carvacrol content. Conclusion: T. spicata represents a promising nutrient for the modulation of gut microbiota and the gut barrier. Further studies must better define its mechanisms of action.
- Published
- 2024
- Full Text
- View/download PDF
36. Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?
- Author
-
Portincasa P, Khalil M, Graziani A, Frühbeck G, Baffy G, Garruti G, Di Ciaula A, and Bonfrate L
- Subjects
- Humans, Obesity therapy, Obesity microbiology, Inflammation, Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Metabolic Syndrome therapy, Fatty Liver
- Abstract
The prevalence of overweight, obesity, type 2 diabetes, metabolic syndrome and steatotic liver disease is rapidly increasing worldwide with a huge economic burden in terms of morbidity and mortality. Several genetic and environmental factors are involved in the onset and development of metabolic disorders and related complications. A critical role also exists for the gut microbiota, a complex polymicrobial ecology at the interface of the internal and external environment. The gut microbiota contributes to food digestion and transformation, caloric intake, and immune response of the host, keeping the homeostatic control in health. Mechanisms of disease include enhanced energy extraction from the non-digestible dietary carbohydrates, increased gut permeability and translocation of bacterial metabolites which activate a chronic low-grade systemic inflammation and insulin resistance, as precursors of tangible metabolic disorders involving glucose and lipid homeostasis. The ultimate causative role of gut microbiota in this respect remains to be elucidated, as well as the therapeutic value of manipulating the gut microbiota by diet, pre- and pro- synbiotics, or fecal microbial transplantation., Competing Interests: Declaration of Competing Interest PP received research grants and speaker fees from Institut Allergosan (Graz, Austria)., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.